The company is undertaking:
• A human clinical trial program focused on insomnia, autism and opioid reduction with activities in Australia and the USA.
• A pre-clinical research program examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.
Zelda managing director Dr Richard Hopkins will present to investors at the Sydney investor event on Monday, May 13 and at the Melbourne event on Tuesday, May 14.
Range of commercialisation opportunities
Zelda’s recent developments include a heads of agreement (HoA) with medicinal cannabis company Ilera Healthcare to explore collaborative opportunities and being granted a new patent covering a novel method to predict patient disease-free survival.
The range of commercialisation opportunities with US-based Ilera include licensing of Zelda products, co-development and data sharing.
Zelda’s Australian patent details a method for detecting levels of expression of a novel receptor complex containing proteins HER2 and CB2.
HER2 is a recognised marker of aggressive breast cancer while CB2 is a key receptor in the endocannabinoid system.
Register for the CEO Sessions today